the potential of cs1-targeted car-t therapy in multiple myeloma
Published 1 year ago • 38 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
0:54
ucartcs1: a novel allogeneic car-t therapy for myeloma
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel
-
2:35
latest advances in car-t for multiple myeloma: cilta-cel & new car-t platforms
-
2:05
novel car-t constructs being explored in myeloma: t-charge platform
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:03:30
memory cd8 t cell differentiation
-
14:28
cluster of differentiation
-
13:01
defects in t cell immunity
-
3:27
car-t cells in myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:35
inflammatory biomarkers as predictors of car-t efficacy in multiple myeloma
-
8:11
current car-t climate in multiple myeloma
-
2:27
horizon scan of car-t in multiple myeloma
-
5:46
where in the treatment sequence should car t-cells be used for myeloma?
-
1:53
the future of multiple myeloma treatment
-
4:15
car-t cells: current climate and future perspectives in multiple myeloma
-
1:45
targetting bcma in myeloma
-
3:07
the role of bridging and timing in car-t
-
2:25
pre-clinical activity of ucartcs1 in multiple myeloma
-
1:59
myeloma: bites & cars
-
2:58
cd1c-restricted t cells as a potential immunotherapy for leukemia